Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) SVP Richard William Scalzo sold 1,343 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $11.38, for a total transaction of $15,283.34. Following the completion of the transaction, the senior vice president now owns 122,330 shares in the company, valued at $1,392,115.40. This represents a 1.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Dyne Therapeutics Stock Down 3.9 %
Shares of NASDAQ:DYN opened at $11.88 on Friday. Dyne Therapeutics, Inc. has a fifty-two week low of $11.18 and a fifty-two week high of $47.45. The firm's 50-day simple moving average is $15.10 and its 200-day simple moving average is $25.73. The company has a market cap of $1.34 billion, a price-to-earnings ratio of -3.34 and a beta of 1.11.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. On average, research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the business. FMR LLC boosted its position in shares of Dyne Therapeutics by 69.7% during the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company's stock worth $324,239,000 after purchasing an additional 3,707,734 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in Dyne Therapeutics by 47.3% during the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company's stock worth $244,755,000 after buying an additional 2,189,339 shares in the last quarter. Jefferies Financial Group Inc. acquired a new position in Dyne Therapeutics during the fourth quarter worth about $42,408,000. Norges Bank purchased a new position in Dyne Therapeutics in the fourth quarter valued at about $22,384,000. Finally, Point72 Asset Management L.P. increased its holdings in Dyne Therapeutics by 802.3% in the fourth quarter. Point72 Asset Management L.P. now owns 924,681 shares of the company's stock valued at $21,785,000 after buying an additional 822,201 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.
Wall Street Analyst Weigh In
DYN has been the topic of a number of recent analyst reports. Scotiabank assumed coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 target price on the stock. Baird R W upgraded Dyne Therapeutics to a "strong-buy" rating in a research report on Thursday, December 12th. BMO Capital Markets began coverage on Dyne Therapeutics in a research report on Wednesday. They issued an "outperform" rating and a $50.00 target price for the company. HC Wainwright dropped their price target on Dyne Therapeutics from $55.00 to $46.00 and set a "buy" rating on the stock in a research note on Friday, February 28th. Finally, Robert W. Baird started coverage on Dyne Therapeutics in a research note on Friday, December 13th. They issued an "outperform" rating and a $46.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $48.85.
Read Our Latest Research Report on DYN
About Dyne Therapeutics
(
Get Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
